These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 17125911)

  • 1. KLF6 IVS1 -27G>A variant and the risk of prostate cancer in Finland.
    Seppälä EH; Autio V; Duggal P; Ikonen T; Stenman UH; Auvinen A; Bailey-Wilson JE; Tammela TL; Schleutker J
    Eur Urol; 2007 Oct; 52(4):1076-81. PubMed ID: 17125911
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutation screening and association study of the candidate prostate cancer susceptibility genes MSR1, PTEN, and KLF6.
    Bar-Shira A; Matarasso N; Rosner S; Bercovich D; Matzkin H; Orr-Urtreger A
    Prostate; 2006 Jul; 66(10):1052-60. PubMed ID: 16598737
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular and Clinicopathological Aspects of Prostate Cancer in Bulgarian Probands.
    Tsvetkova A; Todorova A; Todorov T; Georgiev G; Drandarska I; Mitev V
    Pathol Oncol Res; 2015 Sep; 21(4):969-76. PubMed ID: 25753984
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ser217Leu polymorphism of the HPC2/ELAC2 gene associated with prostatic cancer risk in Japanese men.
    Takahashi H; Lu W; Watanabe M; Katoh T; Furusato M; Tsukino H; Nakao H; Sudo A; Suzuki H; Akakura K; Ikemoto I; Asano K; Ito T; Wakui S; Muto T; Hano H
    Int J Cancer; 2003 Nov; 107(2):224-8. PubMed ID: 12949798
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A germline DNA polymorphism enhances alternative splicing of the KLF6 tumor suppressor gene and is associated with increased prostate cancer risk.
    Narla G; Difeo A; Reeves HL; Schaid DJ; Hirshfeld J; Hod E; Katz A; Isaacs WB; Hebbring S; Komiya A; McDonnell SK; Wiley KE; Jacobsen SJ; Isaacs SD; Walsh PC; Zheng SL; Chang BL; Friedrichsen DM; Stanford JL; Ostrander EA; Chinnaiyan AM; Rubin MA; Xu J; Thibodeau SN; Friedman SL; Martignetti JA
    Cancer Res; 2005 Feb; 65(4):1213-22. PubMed ID: 15735005
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CCR2 and CCR5 genes polymorphisms in benign prostatic hyperplasia and prostate cancer.
    Zambra FM; Biolchi V; Brum IS; Chies JA
    Hum Immunol; 2013 Aug; 74(8):1003-8. PubMed ID: 23632061
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Kruppel-like factor 6 germ-line mutations are infrequent in Finnish hereditary prostate cancer.
    Koivisto PA; Hyytinen ER; Matikainen M; Tammela TL; Ikonen T; Schleutker J
    J Urol; 2004 Aug; 172(2):506-7. PubMed ID: 15247715
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased risk of prostate cancer and benign prostatic hyperplasia associated with transforming growth factor-beta 1 gene polymorphism at codon10.
    Li Z; Habuchi T; Tsuchiya N; Mitsumori K; Wang L; Ohyama C; Sato K; Kamoto T; Ogawa O; Kato T
    Carcinogenesis; 2004 Feb; 25(2):237-40. PubMed ID: 14604900
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenetics of prostate cancer and benign hyperplasia--the potential use of an HLA-G variant as a tag SNP for prostate cancer risk.
    Zambra FM; Biolchi V; de Cerqueira CC; Brum IS; Castelli EC; Chies JA
    HLA; 2016 Feb; 87(2):79-88. PubMed ID: 26889902
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted inhibition of the KLF6 splice variant, KLF6 SV1, suppresses prostate cancer cell growth and spread.
    Narla G; DiFeo A; Yao S; Banno A; Hod E; Reeves HL; Qiao RF; Camacho-Vanegas O; Levine A; Kirschenbaum A; Chan AM; Friedman SL; Martignetti JA
    Cancer Res; 2005 Jul; 65(13):5761-8. PubMed ID: 15994951
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Histological inflammation and risk of subsequent prostate cancer among men with initially elevated serum prostate-specific antigen (PSA) concentration in the Finnish prostate cancer screening trial.
    Yli-Hemminki TH; Laurila M; Auvinen A; Määttänen L; Huhtala H; Tammela TL; Kujala PM
    BJU Int; 2013 Oct; 112(6):735-41. PubMed ID: 23746332
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prostate genetic score (PGS-33) is independently associated with risk of prostate cancer in the PLCO trial.
    Liss MA; Xu J; Chen H; Kader AK
    Prostate; 2015 Sep; 75(12):1322-8. PubMed ID: 25982801
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Associations between polymorphisms in the steroid 5-alpha reductase type II (SRD5A2) gene and benign prostatic hyperplasia and prostate cancer.
    Salam MT; Ursin G; Skinner EC; Dessissa T; Reichardt JK
    Urol Oncol; 2005; 23(4):246-53. PubMed ID: 16018939
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Kruppel-like factor 6 genotype is associated with fibrosis in nonalcoholic fatty liver disease.
    Miele L; Beale G; Patman G; Nobili V; Leathart J; Grieco A; Abate M; Friedman SL; Narla G; Bugianesi E; Day CP; Reeves HL
    Gastroenterology; 2008 Jul; 135(1):282-291.e1. PubMed ID: 18515091
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Insulin-like growth factor-binding protein-3 gene -202 A/C polymorphism is correlated with advanced disease status in prostate cancer.
    Wang L; Habuchi T; Tsuchiya N; Mitsumori K; Ohyama C; Sato K; Kinoshita H; Kamoto T; Nakamura A; Ogawa O; Kato T
    Cancer Res; 2003 Aug; 63(15):4407-11. PubMed ID: 12907612
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HOXB13 G84E mutation in Finland: population-based analysis of prostate, breast, and colorectal cancer risk.
    Laitinen VH; Wahlfors T; Saaristo L; Rantapero T; Pelttari LM; Kilpivaara O; Laasanen SL; Kallioniemi A; Nevanlinna H; Aaltonen L; Vessella RL; Auvinen A; Visakorpi T; Tammela TL; Schleutker J
    Cancer Epidemiol Biomarkers Prev; 2013 Mar; 22(3):452-60. PubMed ID: 23292082
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of codon 10 polymorphism of the transforming growth factor beta 1 gene with prostate cancer and hyperplasia in an Iranian population.
    Omrani MD; Taghipour-Bazargani S; Salari-Lak S; Bagheri M
    Urol Int; 2009; 83(3):329-32. PubMed ID: 19829035
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression analysis of osteopontin mRNA splice variants in prostate cancer and benign prostatic hyperplasia.
    Tilli TM; Thuler LC; Matos AR; Coutinho-Camillo CM; Soares FA; da Silva EA; Neves AF; Goulart LR; Gimba ER
    Exp Mol Pathol; 2012 Feb; 92(1):13-9. PubMed ID: 21963599
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Variants in the prostate-specific antigen (PSA) gene and prostate cancer risk, survival, and circulating PSA.
    Severi G; Hayes VM; Neufing P; Padilla EJ; Tilley WD; Eggleton SA; Morris HA; English DR; Southey MC; Hopper JL; Sutherland RL; Boyle P; Giles GG
    Cancer Epidemiol Biomarkers Prev; 2006 Jun; 15(6):1142-7. PubMed ID: 16775173
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Calculated fast-growing benign prostatic hyperplasia--a risk factor for developing clinical prostate cancer.
    Hammarsten J; Högstedt B
    Scand J Urol Nephrol; 2002; 36(5):330-8. PubMed ID: 12487736
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.